Fiche publication
Date publication
mai 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr FUMET Jean-David
,
Dr BELLIO Hélène
Tous les auteurs :
Bellio H, Fumet JD, Ghiringhelli F
Lien Pubmed
Résumé
Colorectal cancer (CRC) is still one of the most frequent forms of cancer in the world in terms of incidence. Around 40% of CRC patients carry a mutation of the Kirsten rat sarcoma (KRAS) gene, while 10% have a mutation in the B-Raf proto-oncogene serine/threonine kinase (BRAF) gene. These mutations are responsible for dysregulation of the mitogen-associated protein kinase (MAPK) pathway, leading to the proliferation, differentiation, angiogenesis, and resistance to apoptosis of cells. Activation of the MAPK pathway results in adaptive therapeutic resistance, rendering EGFR inhibitors ineffective. This review aims to highlight the recent findings that have improved our understanding of KRAS and BRAF mutations in colorectal cancer and to describe new targeted therapies, used alone or in combination.
Mots clés
BRAF, KRAS, colorectal cancer, targeted therapy
Référence
Cancers (Basel). 2021 May 3;13(9):
